Navigation Links
Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly
Date:5/16/2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2008)... Dr. Alan Greene from the kids, health we...ating only organic food. It,s the same benchmark t...ic. , Danville, CA (PRWEB...ertified organic by the Department of Agriculture ...Alan Greene, why not people?, , , , ,In an articl...
(Date:12/4/2008)... Cell Therapeutics, Inc. ...oday announced that that its Board,of Directors h...fer to,purchase a portion or all of five series o... , -- 4% Convertible Senior Subordinated Note...due 2011, -- 6.75% Convertible Senior Notes du...
(Date:12/4/2008)...n of lung disease in cystic fibrosis (CF), combine... key to controlling the progression of the disease...that contrary to previous scientific opinion, prog...rly as infancy even though lung function shortly a...o stop some of the lung function reduction we,re i...
(Date:12/4/2008)...ec. 4 In the 1983 movie... the world that a Red Ryder BB gun is the perfect ...the response he got from his parents, teacher and ...nd memorable quotes from this Christmas classic be...ldhood. And unfortunately, it comes true for too m...
Breaking Medicine News(10 mins):Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 2Health News:Dr. Alan Greene: The Organic Man -- Renowned Pediatrician Marks Third Anniversary of Organic-Only Diet 3Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 2Health News:Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes 3Health News:Intervention in infants with cystic fibrosis key to slowing progression 2Health News:Intervention in infants with cystic fibrosis key to slowing progression 3Health News:Texas Parents Can Prevent Holiday Tragedies with Safe Toys and Celebrations 2
...here are certain conditions under which they loose... proteins leading to protein aggregation called as...e for causing neurodegenerative disorders such as ...am from Universitat Autònoma de Barcelona, led by ...
...be effectively fused with other cells to work else...ng to a study.// Researchers at Oregon Health and ...cells may be useful in fighting disease. The rese...Grompe, showed that mice with a disease called tyr...
...Wednesday doctors and hospitals in the global heal...Rs 100 million.// Six hospitals in Chennai, two in... residences of 14 prominent doctors were raided by...Rs.6 million in cash as well as fixed deposits and...
...e responsible for transferring the amino acid Cyst...ucing oxidative stress as Cysteine present in glut...nging activity in brain.// Free radicals are respo...y antioxidants. Professor Raymond Swanson and his ...
Other Medicine News:
(Date:12/3/2008)... potential in newly diagnosed patients with a life...o oral sessions at ASH , , - Exjade results...d patients by significantly reducing toxic iron th...m data from major independent breast cancer trial ...nt strategy, Femara vs. tamoxifen , , - Mul...
(Date:12/3/2008)...irstCall/ -- Wyeth Pharmaceuticals,a division of... submitted a,marketing authorization application ... approval to market its investigational 13-valent ...s and young children. Wyeth is seeking an,indica...D) caused by the 13,serotypes included in the inv...
(Date:12/2/2008)... -- Researchers using functional,MRI (fMRI) have ...rain,responsible for suppressing memory is dysfun... psychiatric disorders. Results of the study will ...adiological Society of North America,(RSNA). , ... stress-related disorders,traumatic memories are...
(Date:12/2/2008)...rizon Therapeutics, Inc., a,privately held biopha...tal,Phase 3 trials evaluating its lead investigat... endpoints. HZT-501, a novel, proprietary fixed-do...amotidine, demonstrated a,statistically significa...ti-inflammatory drug (NSAID)-induced upper gastroi...
Breaking Medicine Technology:More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 2More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 3More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 4More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 5More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 6More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 7More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 8More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 9More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 10More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 11More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 12More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 13More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 14More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 15More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 16More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 17More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 18More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 19More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 20More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 21More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies 22Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference 8642 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 1Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 27859 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 1LCA Vision Reports Third Quarter 2008 Financial Results 27857 2LCA Vision Reports Third Quarter 2008 Financial Results 27857 3LCA Vision Reports Third Quarter 2008 Financial Results 27857 4LCA Vision Reports Third Quarter 2008 Financial Results 27857 5LCA Vision Reports Third Quarter 2008 Financial Results 27857 6LCA Vision Reports Third Quarter 2008 Financial Results 27857 7LCA Vision Reports Third Quarter 2008 Financial Results 27857 8LCA Vision Reports Third Quarter 2008 Financial Results 27857 9LCA Vision Reports Third Quarter 2008 Financial Results 27857 10LCA Vision Reports Third Quarter 2008 Financial Results 27857 11LCA Vision Reports Third Quarter 2008 Financial Results 27857 12LCA Vision Reports Third Quarter 2008 Financial Results 27857 13Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 1Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 2Frost 26 Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards 27855 3
...ON, March 06, 2007 /PRNewswire/ -- Up to two milli...p to 600,000,hospitalized. Its primary complicatio...ives annually -- more than breast cancer and,AIDS ...sease may be,at increased risk for DVT, because th...clots and pooling. Respiratory tract infection,may...
...E, Mass., March 06, 2007 /PRNewswire-FirstCall/ --... three completed,Phase III multi- center clinical ...acement therapeutic will be presented during,the N...al Meetings,taking place April 10th through 14th i...a are scheduled to be presented on,Wednesday, Apri...
Other Medicine Technology:DVT Awareness Survey Findings: Heart and Respiratory Patients 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 2Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 3Advanced Magnetics Announces Presentation of Ferumoxytol Data at,the National Kidney Foundation 2007 Spring Clinical Meetings 4
... at Once , To increase efficiency and throughput ... adapt to the narrow well spacing. Thats exactly w... Available with Impact or Impact2 software (see Im...signed to allow you to transfer an entire column o...
Designed to create a near bloodless field and provide myocardial protection during target vessel anastomosis. Its unique internal coil and tapered tip have been designed to allow easy, atraumatic ins
...y is used for cardiac and great vessel reconstruct...araldehyde-treated bovine pericardium and offers s...suturability and handling over synthetic patches. ... ability to prevent calcification and the complica...
Supreme and Response catheters comprise the world's broadest line of fixed-curve catheters available for electrophysiology procedures. Their advanced catheter design and materials technology provide
Medicine Products: